Clinicopathological Characteristics and Therapeutic Response to Concurrent Chemoradiotherapy in Stage IIB–IVA Cervical Cancer

Niken Amalia Gandini, Oky Haribudiman, Wiryawan Permadi


Abstract


Objectives: This study aimed to describe the response to concurrent chemoradiotherapy in stage IIB–IVA cervical cancer and its association with histopathological subtype, age, stage, and tumor size.

Methods: This retrospective analytical cross-sectional study reviewed the records of 109 women who completed external beam radiotherapy, intracavitary brachytherapy, and weekly cisplatin at Al Ihsan Regional General Hospital, West Java, from 2022 to 2024. Response was assessed approximately three months after treatment using the Response Evaluation Criteria in Solid Tumors version 1.1. Histopathological subtype was analyzed using the Fisher–Freeman–Halton exact test, whereas age, stage, and tumor size were analyzed using Spearman rank correlation.

Results: Complete response occurred in 77.1% of women, partial response in 18.3%, stable disease in 3.7%, and progressive disease in 0.9%. Complete response rates were 77.3% in squamous cell carcinoma (80.7% of women), 82.4% in adenocarcinoma, and 50.0% in adenosquamous carcinoma (4 women). Complete response rates were 84.6% in stage IIB and 73.8% in stage IIIB; these two stages together comprised 95.4% of women. No variable was significantly associated with response (all p > 0.05).

Conclusion: Most women achieved a complete response after concurrent chemoradiotherapy. Response was not significantly associated with histopathological subtype, age, stage, or tumor size, although the small number of non-squamous and stage IVA cases limits this finding. Larger prospective studies are needed.


Karakteristik Klinikopatologis dan Respons Terapi Kemoradiasi Konkuren pada Kanker Serviks Stadium IIB–IVA

Abstrak

Tujuan: Penelitian ini bertujuan menggambarkan respons kemoradiasi konkuren pada kanker serviks stadium IIB–IVA serta hubungannya dengan jenis histopatologi, usia, stadium, dan ukuran tumor.

Metode: Penelitian analitik potong lintang retrospektif ini menelaah rekam medis 109 perempuan yang menyelesaikan radioterapi eksterna, brakiterapi intrakaviter, dan sisplatin mingguan di Rumah Sakit Umum Daerah Al Ihsan, Jawa Barat, pada tahun 2022–2024. Respons dinilai kurang lebih tiga bulan setelah terapi menggunakan Response Evaluation Criteria in Solid Tumors versi 1.1. Jenis histopatologi dianalisis dengan uji eksak Fisher–Freeman–Halton, sedangkan usia, stadium, dan ukuran tumor dianalisis dengan uji korelasi peringkat Spearman.

Hasil: Respons komplet terjadi pada 77,1% perempuan, respons parsial 18,3%, penyakit stabil 3,7%, dan penyakit progresif 0,9%. Karsinoma sel skuamosa paling banyak ditemukan (80,7%). Angka respons komplet adalah 77,3% pada karsinoma sel skuamosa, 82,4% pada adenokarsinoma, dan 50,0% pada karsinoma adenoskuamosa (4 perempuan). Respons komplet sebesar 84,6% pada stadium IIB dan 73,8% pada stadium IIIB, yang bersama-sama mencakup 95,4% perempuan. Tidak ada variabel yang berhubungan bermakna dengan respons (seluruh p > 0,05).

Kesimpulan: Sebagian besar perempuan mencapai respons komplet setelah kemoradiasi konkuren. Respons tidak berhubungan bermakna dengan jenis histopatologi, usia, stadium, maupun ukuran tumor, meskipun jumlah kasus nonskuamosa dan stadium IVA yang sedikit membatasi temuan ini. Diperlukan penelitian prospektif dengan jumlah sampel yang lebih besar.


Keywords


Cervical cancer; chemoradiotherapy; histopathology; locally advanced; therapeutic response

Full Text:

PDF

References


Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. doi: 10.3322/caac.21660

Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–203. doi: 10.1016/S2214-109X(19)30482-6

Zhang X, Zeng Q, Cai W, Ruan W. Trends of cervical cancer at global, regional, and national level: data from the Global Burden of Disease study 2019. BMC Public Health. 2021;21(1):894. doi: 10.1186/s12889-021-10907-5

Yang M, Du J, Lu H, Xiang F, Mei H, Xiao H. Global trends and age-specific incidence and mortality of cervical cancer from 1990 to 2019: an international comparative study based on the Global Burden of Disease. BMJ Open. 2022;12(7):e055470. doi: 10.1136/bmjopen-2021-055470

Tjokroprawiro BA, Novitasari K, Saraswati W, Yuliati I, Ulhaq RA, Sulistya HA. The challenging journey of cervical cancer diagnosis and treatment at the second largest hospital in Indonesia. Gynecol Oncol Rep. 2024;51:101325. doi: 10.1016/j.gore.2024.101325

Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018;143 Suppl 2:22–36. doi: 10.1002/ijgo.12611

Cibula D, Raspollini MR, Planchamp F, Centeno C, Chargari C, Felix A, et al. ESGO/ESTRO/ESP guidelines for the management of patients with cervical cancer - update 2023. Int J Gynecol Cancer. 2023;33(5):649–66. doi: 10.1136/ijgc-2023-004429

Manso L, Ramchandani-Vaswani A, Romero I, Sánchez-Lorenzo L, Bermejo-Pérez MJ, Estévez-García P, et al. SEOM-GEICO clinical guidelines on cervical cancer (2023). Clin Transl Oncol. 2024;26(11):2771–82. doi: 10.1007/s12094-024-03604-3

He ZY, Li HY, Yan J, Li SJ, Li DC, Liang ZZ. A prospective trial to evaluate the clinical efficacy and safety of neoadjuvant chemotherapy with arsenic trioxide and carboplatin in locally advanced cervical cancer: a study protocol for randomized controlled clinical. Trials. 2022;23(1):556. doi: 10.1186/s13063-022-06489-1

Green JA, Kirwan JJ, Tierney J, Vale CL, Symonds PR, Fresco LL, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2005;(3):CD002225. doi: 10.1002/14651858.CD002225.pub2

Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26(35):5802–12. doi: 10.1200/JCO.2008.16.4368

Gonçalves WJ. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Sao Paulo Med J. 2010;128(3):177–8. doi: 10.1590/S1516-31802010000300011

Yao G, Qiu J, Zhu F, Wang X. Survival of patients with cervical cancer treated with definitive radiotherapy or concurrent chemoradiotherapy according to histological subtype: a systematic review and meta-analysis. Front Med (Lausanne). 2022;9:843262. doi: 10.3389/fmed.2022.843262

Gallardo-Alvarado L, Cantú-de León D, Ramirez-Morales R, Santiago-Concha G, Barquet-Muñoz S, Salcedo-Hernandez R, et al. Tumor histology is an independent prognostic factor in locally advanced cervical carcinoma: a retrospective study. BMC Cancer. 2022;22(1):401. doi: 10.1186/s12885-022-09506-3

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. doi: 10.1016/j.ejca.2008.10.026

Liu YM, Ni LQ, Wang SS, Lv QL, Chen WJ, Ying SP. Outcome and prognostic factors in cervical cancer patients treated with surgery and concurrent chemoradiotherapy: a retrospective study. World J Surg Oncol. 2018;16(1):18. doi: 10.1186/s12957-017-1307-0

Zhang GY, Zhang R, Bai P, Li SM, Zhang YY, Chen YR, et al. Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study. BMC Cancer. 2022;22(1):1331. doi: 10.1186/s12885-022-10406-9

Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ. 1995;311(7003):485. doi: 10.1136/bmj.311.7003.485

Voinea S, Herghelegiu CG, Sandru A, Ioan RG, Bohilțea RE, Bacalbașa N, et al. Impact of histological subtype on the response to chemoradiation in locally advanced cervical cancer and the possible role of surgery. Exp Ther Med. 2021;21(1):93. doi: 10.3892/etm.2020.9525

Lin C, Xiao N, Chen Q, Liao D, Yang F, Liu P, et al. Prognostic implications of tumor volume reduction during radiotherapy in locally advanced cervical cancer: a risk-stratified analysis. Radiat Oncol. 2025;20(1):47. doi: 10.1186/s13014-025-02623-w

Katanyoo K, Thavaramara T. Clinical impact of pelvic lymph node status in locally advanced cervical cancer patients treated by concurrent chemoradiation therapy. Asian Pac J Cancer Prev. 2021;22(2):491–7. doi: 10.31557/APJCP.2021.22.2.491




DOI: http://dx.doi.org/10.24198/obgynia.v9i3.1294

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.


     
  

Creative Commons License
Indonesian Journal of Obstetrics & Gynecology Science is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. 
  Web Analytics
  View My Stat